GFR decline as an end point for clinical trials in CKD: A view from Europe

American Journal of Kidney Diseases

Volumn 64, Issue 6, 2014, Pages 838-840

  Mol, Peter G M ^a,b   Maciulaitis, Romaldas ^c,d   Vetter, Thorsten ^e  

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c State Medicine Control Agency of Lithuania   (Lithuania)

^d LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^e EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DISEASE COURSE; END STAGE RENAL DISEASE; EUROPE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTEIN RESTRICTION; REVIEW; SECONDARY PREVENTION; WORKSHOP; BIOASSAY; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STANDARDS;

ENDPOINT DETERMINATION; EUROPE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 84910666073     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.10.001     Document Type: Editorial

References (19)

1. R. Temple Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282 8 1999 790 795
2. E. Blind, K. Dunder, P.A. de Graeff, and E. Abadie Rosiglitazone: A European regulatory perspective Diabetologia 54 2 2011 213 218
3. European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn [niacin/laropiprant] [press release]. European Medicines Agency; 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/01/news-detail-001694.jsp&mid=WC0b01ac058004d5c1. Accessed September 30, 2014.
4. European Medicines Agency recommends suspension of marketing authorisation for sibutramine [press release]. European Medicines Agency; 2010. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2010/01/news-detail-000985.jsp&mid=WC0b01ac058004d5c1. Accessed September 30, 2014.
5. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia [rimonabant] [press release]. European Medicines Agency; 2008. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2009/11/news-detail-000244.jsp&mid=WC0b01ac058004d5c1. Accessed September 30, 2014.
6. W.R. Hiatt, and R.J. Smith Assessing the clinical benefits of lipid-disorder drugs N Engl J Med 370 5 2014 396 399
7. B.M. Scirica, D.L. Bhatt, and E. Braunwald Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 14 2013 1317 1326
8. W.B. White, C.P. Cannon, and S.R. Heller Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 14 2013 1327 1335
9. D. Cohen New oral hypoglycaemics fail to show cardiovascular benefits BMJ 347 2013 f5458
10. L.A. Inker, H.J. Lambers Heerspink, and H. Mondal GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials Am J Kidney Dis 64 6 2014 848 859
11. H.J. Lambers Heerspink, H. Tighiouart, and Y. Sang GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials Am J Kidney Dis 64 6 2014 860 866
12. T. Greene, J. Teng, and L.A. Inker Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study Am J Kidney Dis 64 6 2014 867 879
13. A.S. Levey, L.A. Inker, and K. Matsushita GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 64 4 2014 821 835
14. European Medicines Agency. Draft guideline on the clinical investigation of medicinal products to prevent development/slow progression of chronic renal insufficiency (EMA/CHMP/355988/2014). 2014. http://www.ema.europa.eu/ema/doc-index.jsp?curl=pages/includes/document/document-detail.jsp?webContentId=WC500169469&murl=menus/document-library/document-library.jsp&mid=0b01ac058009a3dc. Accessed September 30, 2014.
15. F.A. Holtkamp, D. de Zeeuw, and M.C. Thomas An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function Kidney Int 80 3 2011 282 287
16. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 311(24):2518-2531.
17. P.A. Smink, Y. Miao, and M.J. Eijkemans The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers Clin Phar Ther 95 2 2014 208 215
18. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on the Scientific Application and the Practical Arrangements Necessary to Implement Commission Regulation (EC) No 507/2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation (EC) No 726/2004. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/10/WC500004908.pdf. Accessed September 30, 2014.
19. European Medicines Agency launches adaptive licensing pilot project [press release]. European Medicines Agency; 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2014/03/news-detail-002046.jsp&mid=WC0b01ac058004d5c1. Accessed September 30, 2014.